Epidermal growth factor receptor (EGFR) mutations play an important role in both the development and the progression of non-small cell lung cancer (NSCLC).1,2 The deletion of exon 19 (19del) as well as the point mutation of L858R are considered to be classical and common EGFR mutations, and account for 80%-90% of all EGFR mutations.1-3 In addition, other types of EGFR mutations, known as uncommon EGFR mutations, also have been reported, represent approximately 10%-15% of all EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.